Individuals at Risk for Depression Clinical Trial
— AIMOfficial title:
Technology Assisted Behavioral Intervention for the Prevention of Depression
| Verified date | June 2012 |
| Source | Northwestern University |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | United States: Federal Government |
| Study type | Interventional |
This study will develop and evaluate the effectiveness of a technology-assisted behavioral intervention, consisting of Internet-based cognitive behavioral therapy combined with telephone and email support, in preventing depressive symptoms and improving treatment adherence in individuals at risk of major depressive disorder.
| Status | Withdrawn |
| Enrollment | 0 |
| Est. completion date | December 2013 |
| Est. primary completion date | December 2013 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | Both |
| Age group | 19 Years and older |
| Eligibility |
Inclusion Criteria: - PredictD Risk Score of .130 - Has a telephone, e-mail account, computer, and broadband access to the Internet. - Is able to speak and read English. - Is at least 19 years of age. - Is able to give informed consent. Exclusion Criteria: - Has DSM-IV diagnosis of Major Depressive Episode assessed using the MINI - Has hearing or voice impairment that would prevent participation in psychotherapy. - Has visual impairment that would prevent use of the workbook and completion of assessment materials. - Meets criteria for dementia by scoring < 25 on the Telephone Interview for Cognitive Status (TICS). - Is diagnosed with a psychotic disorder, bipolar disorder, dissociative disorder, current post-traumatic stress disorder (PTSD), current substance abuse, or other diagnosis for which participation in a clinical trial of psychotherapy may be either inappropriate or dangerous. Patients with substance abuse diagnoses who have been clean and sober for 3 months will be admitted if otherwise eligible. - Is currently receiving individual psychotherapy or planning to receive psychotherapy during the 12-week treatment phase of the study. - Is planning to be out of town or unavailable for treatment for 4 weeks or more during the scheduled treatment time. - Exhibits severe suicidality, including ideation, plan, and intent. - Has initiated treatment with an antidepressant in past 10 days. Once patients have been on a stable dose for 10 days and do not have an appointment with a physician or psychiatrist to change this dose, the patient will be eligible based on this criterion. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention
| Country | Name | City | State |
|---|---|---|---|
| United States | Northwestern University | Chicago | Illinois |
| Lead Sponsor | Collaborator |
|---|---|
| Northwestern University |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Depression, as assessed by Quick Inventory of Depressive Symptoms (QIDS), the Patient Health Questionnaire-9 (PHQ-9), and the Mini International Neuropsychiatric Interview (MINI) Disorders-Major Depressive Disorders Module | Measured at baseline, week 6, week 12 and month 3, month 6, month 9 and month 12 | No | |
| Primary | Website utilization (e.g., number of logins, average visit length, total time spent on the site, number of exercises completed), Attrition and cost effectiveness. | From baseline through 12 month follow-up | No | |
| Secondary | Anxiety, impact on work, social support | Measured at baseline, week 6, week 12 and month 3, month 6, month 9 and month 12 | No |